Efforts to develop safer members of a therapeutic class must carry the burden of their toxic forebears, a risk that may have snagged Eli Lilly and Co. in its effort to develop a selective serotonin receptor agonist identified as part of the pharma company's collaboration with Synaptic Pharmaceutical Corp.

Lilly was to have started this month a Phase III trial